SCHEDULE: Adage Capital Management Discloses 5.77% Stake in Centessa Pharma

Adage Capital Management, L.P. and its associated individuals have reported beneficial ownership of 5.77% of Centessa Pharmaceuticals plc's ordinary shares as of March 31, 2026.

Summary

• Adage Capital Management, L.P. (ACM), through its general partner Adage Capital Partners, L.P. (ACP), and associated entities and individuals (Robert Atchinson and Phillip Gross), has filed a Schedule 13G.
• The filing indicates beneficial ownership of 8,925,010 Ordinary Shares of Centessa Pharmaceuticals plc, representing 5.77% of the class.
• These shares are held indirectly through American Depositary Shares (ADSs) quoted on Nasdaq under the symbol 'CNTA'.
• The reporting date for this ownership stake is March 31, 2026.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates significant institutional interest and investment in Centessa Pharmaceuticals, but provides no direct operational or financial updates from the company itself.

Positives

• Adage Capital Management has taken a significant stake (5.77%) in Centessa Pharmaceuticals, which could signal confidence in the company's future prospects.
• The filing indicates that the shares were acquired in the ordinary course of business, suggesting a standard investment strategy rather than a hostile takeover attempt.

Negatives

• The filing does not contain any negative financial results or operational challenges for Centessa Pharmaceuticals.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not detail specific risks faced by Centessa Pharmaceuticals. However, any significant ownership stake by an investment firm inherently carries market risk associated with the company's performance and the broader economic environment.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Centessa Pharmaceuticals. The future outlook for the company would be inferred from its own financial reports and strategic announcements.

Management Comments

• "The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein."
• "I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings often indicate institutional investor conviction. Adage Capital Management's acquisition of a substantial position in Centessa Pharmaceuticals suggests a belief in the company's underlying value or growth potential within the biopharmaceutical sector.

Stakeholder Impact

• Shareholders: The increased institutional interest may be viewed positively, potentially leading to greater liquidity or market attention for the stock.
• Management: The filing confirms that the investment is in the ordinary course of business and not intended to influence control, which may provide some reassurance to current management.
• Creditors: No direct impact is indicated.

Next Steps

• Adage Capital Management will continue to hold or potentially adjust its stake in Centessa Pharmaceuticals.
• Centessa Pharmaceuticals will continue its operations and financial reporting as usual.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership by an investment manager and does not contain operational or financial performance data for Centessa Pharmaceuticals. While the significant stake taken by Adage Capital Management suggests potential positive sentiment, without further company-specific performance metrics or strategic updates, a 'hold' recommendation is prudent for seasoned investors, pending more comprehensive analysis of Centessa's business fundamentals.

Keywords

Centessa Pharmaceuticals, Schedule 13G, Adage Capital Management, Beneficial Ownership, Ordinary Shares, ADSs, Investment, SEC Filing, Robert Atchinson, Phillip Gross